Table 2.
Renal, immunologic and biopsy results.
| Variables | Cohort 1 (N = 45) | P value | Cohort 2 (N = 30) | P value | ||
|---|---|---|---|---|---|---|
| ABMR+ (n = 25) | ABMR− (n = 20) | ABMR+ (n = 17) | ABMR‐ (n = 13) | |||
| Renal parameters | ||||||
| Serum creatinine (mg/dl), median (IQR) | 1.71 (1.23–2.41) | 1.34 (1.19–1.81) | 0.10 | 1.41 (1.15–2.51) | 1.77 (1.17–2.81) | 0.77 |
| Protein/creatinine ratio (mg/g), median (IQR) | 343 (85–863) | 167 (115–224) | 0.041 | 1003 (305–2985) | 318 (221–411) | 0.073 |
| DSA characteristics | ||||||
| HLA class I DSA only, n (%) | 4 (16.0) | 9 (45.0) | 0.03 | 3 (17.6) | 5 (38.5) | 0.20 |
| HLA class II DSA only, n (%) | 14 (56.0) | 7 (35.0) | 0.14 | 11 (64.7) | 5 (38.5) | 0.15 |
| HLA class I and II DSA, n (%) | 7 (28.0) | 4 (20.0) | 0.40 | 3 (17.6) | 3 (23.1) | 0.53 |
| Anti‐DQ DSA, n (%) | 15 (60.0) | 10 (50.0) | 0.36 | 10 (58.8) | 5 (38.5) | 0.23 |
| Number of DSA, median (IQR) | 1 (1–2) | 1 (1–2) | 0.32 | 1 (1–2) | 1 (1–2) | 0.71 |
| DSA‐MFI*, median (IQR) | 4407 (2819–9886) | 1390 (1108–1781) | <0.001 | 8843 (3254–18 195) | 2120 (1461–5345) | 0.007 |
| Biopsy results | ||||||
| ABMR, n (%) | ||||||
| Active ABMR, i (%) | 8 (32.0) | – | – | 3 (17.6) | – | – |
| Chronic active ABMR, n (%) | 16 (64.0) | – | – | 13 (76.5) | – | – |
| Chronic ABMR (inactive), n (%) | 1 (4.0) | – | – | 1 (5.9) | – | – |
| C4d‐positive ABMR, n (%) | 11 (44.0) | – | – | 7 (41.2) | – | ‐ |
| Molecular ABMR score, median (IQR) | 0.65 (0.45–0.87) | 0.08 (0.04–0.13) | <0.001 | – | – | – |
| Banff borderline lesion, n (%) | 3 (12.0) | 2 (10.0) | 0.61 | 1 (5.9) | 0 (0) | 0.57 |
| TCMR, n (%) | 0 (0) | 0 (0) | – | 1 (5.9) | 2 (15.4) | 0.40 |
| BK virus nephropathy, n (%) | 0 (0) | 0 (0) | – | 0 (0) | 1 (7.7) | 0.43 |
| Glomerulonephritis, n (%) | 1 (4.0) | 2 (10.0) | 0.42 | 0 (0) | 3 (23.1) | 0.07 |
ABMR, antibody‐mediated rejection; DSA, donor‐specific antibody; IQR, interquartile range; MFI, mean fluorescence intensity.
*MFI of the immunodominant DSA.